[go: up one dir, main page]

PL2956471T3 - Kompozycja inhibitora il-1beta i jej zastosowanie - Google Patents

Kompozycja inhibitora il-1beta i jej zastosowanie

Info

Publication number
PL2956471T3
PL2956471T3 PL13875211.8T PL13875211T PL2956471T3 PL 2956471 T3 PL2956471 T3 PL 2956471T3 PL 13875211 T PL13875211 T PL 13875211T PL 2956471 T3 PL2956471 T3 PL 2956471T3
Authority
PL
Poland
Prior art keywords
inhibitor composition
1beta
1beta inhibitor
composition
inhibitor
Prior art date
Application number
PL13875211.8T
Other languages
English (en)
Inventor
Yan Lavrovsky
Ting Xu
Alexey REPIK
Tao Xu
Vasily IGNATIEV
Mikhail Samsonov
Original Assignee
R-Pharm International, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51354448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2956471(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by R-Pharm International, Llc filed Critical R-Pharm International, Llc
Publication of PL2956471T3 publication Critical patent/PL2956471T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
PL13875211.8T 2013-02-15 2013-02-15 Kompozycja inhibitora il-1beta i jej zastosowanie PL2956471T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2013/026349 WO2014126582A1 (en) 2013-02-15 2013-02-15 IL-1β INHIBITOR COMPOSITION AND USE THEREOF

Publications (1)

Publication Number Publication Date
PL2956471T3 true PL2956471T3 (pl) 2024-06-24

Family

ID=51354448

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13875211.8T PL2956471T3 (pl) 2013-02-15 2013-02-15 Kompozycja inhibitora il-1beta i jej zastosowanie

Country Status (24)

Country Link
EP (2) EP4050019A1 (pl)
JP (1) JP6225197B2 (pl)
KR (1) KR101989551B1 (pl)
CN (1) CN105431448B (pl)
AU (1) AU2013378122B2 (pl)
BR (1) BR112015019729B1 (pl)
DK (1) DK2956471T3 (pl)
EA (1) EA033269B1 (pl)
ES (1) ES2990881T3 (pl)
FI (1) FI2956471T3 (pl)
HR (1) HRP20240641T1 (pl)
HU (1) HUE067221T2 (pl)
IL (1) IL240553B (pl)
LT (1) LT2956471T (pl)
MX (1) MX390047B (pl)
NZ (1) NZ710900A (pl)
PH (1) PH12015501796B1 (pl)
PL (1) PL2956471T3 (pl)
PT (1) PT2956471T (pl)
RS (1) RS65559B1 (pl)
SG (1) SG11201506389YA (pl)
SI (1) SI2956471T1 (pl)
SM (1) SMT202400191T1 (pl)
WO (1) WO2014126582A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2956471T3 (pl) 2013-02-15 2024-06-24 R-Pharm International, Llc Kompozycja inhibitora il-1beta i jej zastosowanie
US12180264B2 (en) 2014-03-24 2024-12-31 R-Pharm Overseas, Inc. IL1-R1 derived inhibitor of IL-1β and use thereof
CN104628870A (zh) * 2015-02-04 2015-05-20 中国药科大学 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
CN104725514A (zh) * 2015-02-06 2015-06-24 中国药科大学 新型il23拮抗剂
CN110719920B (zh) 2017-06-14 2024-01-30 苏州丁孚靶点生物技术有限公司 蛋白质异二聚体及其用途
EP4541367A3 (en) 2017-09-26 2025-07-30 Regeneron Pharmaceuticals, Inc. Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein
JP7606240B2 (ja) * 2020-05-22 2024-12-25 アール-ファーム・オーバーシーズ・インコーポレイテッド IL-1βのIL1-R1由来のインヒビターおよびその使用
KR20220014531A (ko) 2020-07-29 2022-02-07 (주)메디톡스 헤테로이량체 Fc 융합 단백질, 및 관련 조성물, 용도 및 방법
CN116286844A (zh) * 2023-02-13 2023-06-23 浙江大学 人IL-1R1和人IL-1RAcP多肽片段组合的同源二聚体蛋白质与用途
CN116144668A (zh) * 2023-02-13 2023-05-23 杭州吉倍思生物制药有限公司 人il-1r1基因、蛋白、同源二聚体蛋白质与用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
ES2439709T3 (es) * 2005-06-21 2014-01-24 Xoma (Us) Llc Anticuerpos y fragmentos de los mismos que se unen a la IL-1beta
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
AU2009204501B2 (en) * 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
CN103429619B (zh) 2011-03-17 2017-07-28 雷蒙特亚特特拉维夫大学有限公司 双特异性和单特异性、不对称抗体和其制备方法
WO2014035361A1 (en) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
PL2956471T3 (pl) 2013-02-15 2024-06-24 R-Pharm International, Llc Kompozycja inhibitora il-1beta i jej zastosowanie

Also Published As

Publication number Publication date
JP2016513106A (ja) 2016-05-12
BR112015019729B1 (pt) 2023-01-24
EA201500842A1 (ru) 2016-02-29
LT2956471T (lt) 2024-06-10
PT2956471T (pt) 2024-05-27
EP4050019A1 (en) 2022-08-31
NZ710900A (en) 2019-09-27
HRP20240641T1 (hr) 2025-06-20
MX2015010438A (es) 2016-05-05
IL240553A0 (en) 2015-10-29
MX390047B (es) 2025-03-20
IL240553B (en) 2021-02-28
ES2990881T3 (es) 2024-12-02
FI2956471T3 (fi) 2024-05-13
PH12015501796A1 (en) 2015-11-09
WO2014126582A1 (en) 2014-08-21
CN105431448B (zh) 2019-08-27
JP6225197B2 (ja) 2017-11-01
AU2013378122B2 (en) 2019-05-02
EA033269B1 (ru) 2019-09-30
HUE067221T2 (hu) 2024-10-28
DK2956471T3 (da) 2024-05-21
PH12015501796B1 (en) 2015-11-09
EP2956471A4 (en) 2019-11-13
KR101989551B1 (ko) 2019-09-30
SMT202400191T1 (it) 2024-07-09
KR20160048028A (ko) 2016-05-03
HK1219281A1 (en) 2017-03-31
EP2956471B1 (en) 2024-04-10
RS65559B1 (sr) 2024-06-28
BR112015019729A2 (pt) 2017-07-18
AU2013378122A1 (en) 2015-08-27
SG11201506389YA (en) 2015-09-29
CN105431448A (zh) 2016-03-23
SI2956471T1 (sl) 2024-06-28
EP2956471A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
GB201317286D0 (en) Composition and Use
HUE039504T2 (hu) Kináz inhibitor és alkalmazása
GB201608553D0 (en) Strigolactone formulations and uses thereof
HUE044893T2 (hu) Tûzálló készítmény és annak használata
LT3077467T (lt) Džioviklio kompozicija ir jos panaudojimas
GB201305277D0 (en) Novel combination and use
GB201321693D0 (en) Composition and uses thereof
SG11201508167PA (en) Therapeutic compositions and uses thereof
HUE067221T2 (hu) IL-1béta inhibitor készítmény és annak alkalmazása
GB201301626D0 (en) Composition comprising 15-OHEPA and methods of using the same
GB2519982B (en) Fungicidal composition and the use thereof
EP2976091C0 (de) Antioxidativ wirksame zusammensetzung und deren verwendung
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
SG11201510150VA (en) Immunotherapy composition and use thereof
EP3007720A4 (en) COMPOSITION COMPRISING THE GC MACROPHAGE ACTIVATION FACTOR AND USES THEREOF
PL2910131T3 (pl) Kompozycja przeciwdziałająca zmęczeniu i jej zastosowanie
GB2516838B (en) Fungicidal compositions and their use
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
TWI562776B (en) Pharmaceutical composition and uses thereof
GB201322892D0 (en) Surface and composition
GB201301979D0 (en) New composition and use thereof
GB201318151D0 (en) Composition and device
FR3007291B1 (fr) Composition cicatrisante et utlisation
GB201305297D0 (en) Novel agents and uses thereof
GB2532383B (en) Set-delayed cement compositions comprising pumice and associated methods